Abstracts abusers were 1.5-fold as likely to have medically related absenteeism days, and 8.5 times as likely to have a disability claim compared to controls (p < 0.01). Opioid abusers had higher average annual medically related absenteeism days compared to controls (26.4 days vs. 5.7 days, p < 0.01). Mean annual direct health care costs for opioid abusers were over eight times higher than controls ($15,884 vs. $1830, p < 0.01). Hospital inpatient and doctor/outpatient costs accounted for 46% ($7239) and 31% ($5000) of opioid abusers' health care costs, versus 17% ($310) and 50% ($906), respectively, for controls. Mean annual indirect workloss costs for opioid abusers were over eight times higher than controls ($4167 vs. $502, p < 0.01). CONCLU-SIONS: These high costs were driven partly by high utilization rates of medical services and prescription drugs, and higher prevalence of workloss. Our estimates may be conservative as only patients diagnosed with abuse were included. To the extent that the abuse is prescription opioid abuse, payers should ensure appropriate access to opioids while considering abuse liability of drugs on formulary. OBJECTIVES: To examine use, timing and cost of Emergency Department (ED) visits by those of college age (17-22 years) for acute alcohol intoxication. METHODS: Cases were identified from Massachusetts 2002 ED and hospital databases using ICD-9 principal diagnosis codes 305.00-305.09. Hospital cases were limited to those admitted via ED. Cost estimates include facility, accommodations and ancillary services, reported in 2002 USD. Charges were adjusted using a 0.55 cost-to-charge ratio. RESULTS: Of 1803 cases identified, 52% were male and 55% were less than 20-years old. Ambulances were used to transport 54%; law enforcement was involved in 1.5% of cases. The majority (69%) arrived between 10:00 PM and 4:00 AM, and 70% of all visits occurred Friday through Sunday. Significantly (p = 0.004) more visits occurred in September and October than any other month. The majority (94%) were treated and released from ED, 1% was hospitalized, 2% eloped or left AMA, 2% were transferred and 1% was recorded as unknown. Mean duration of ED visit was 5.4 hours (median: 4). Mean cost per ED visit was $482 (median: $382) for those treated and released, and $537 (median: $460) for those hospitalized. On average, those admitted (n = 20) spent 2.5 days (median: 1) in the hospital at a cost of $4540 (median: $2154). The cumulative hours of ED time used in one year for treating alcohol intoxication in this age group was 8254. Cumulative cost of ED and inpatient care for the year was roughly $938,000. Managed care organizations and commercial insurers were the responsible payers for most cases (60%). Self-pay was noted for 24%. CONCLU-SIONS: Acute alcohol intoxication among those of college age results in a substantial direct medical cost, as well as an opportunity cost for ED resources during the year, particularly at the start of the school year.
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(For abstract PMH2 see page 256) MH2 EMERGENCY DEPARTMENT USE FOR ACUTE ALCOHOL INTOXICATION BY COLLEGE AGE PERSONS: TIME AND COST OF TREATMENT
O'Brien JA 1 , Pitoniak-Morse C 1 , Jacobs LM 2 1 Caro Research Institute, Concord, MA, USA; 2 University of Connecticut Medical School, Farmington, CT, USA OBJECTIVES: To examine use, timing and cost of Emergency Department (ED) visits by those of college age (17-22 years) for acute alcohol intoxication. METHODS: Cases were identified from Massachusetts 2002 ED and hospital databases using ICD-9 principal diagnosis codes 305.00-305.09. Hospital cases were limited to those admitted via ED. Cost estimates include facility, accommodations and ancillary services, reported in 2002 USD. Charges were adjusted using a 0.55 cost-to-charge ratio. RESULTS: Of 1803 cases identified, 52% were male and 55% were less than 20-years old. Ambulances were used to transport 54%; law enforcement was involved in 1.5% of cases. The majority (69%) arrived between 10:00 PM and 4:00 AM, and 70% of all visits occurred Friday through Sunday. Significantly (p = 0.004) more visits occurred in September and October than any other month. The majority (94%) were treated and released from ED, 1% was hospitalized, 2% eloped or left AMA, 2% were transferred and 1% was recorded as unknown. Mean duration of ED visit was 5.4 hours (median: 4). Mean cost per ED visit was $482 (median: $382) for those treated and released, and $537 (median: $460) for those hospitalized. On average, those admitted (n = 20) spent 2.5 days (median: 1) in the hospital at a cost of $4540 (median: $2154). The cumulative hours of ED time used in one year for treating alcohol intoxication in this age group was 8254. Cumulative cost of ED and inpatient care for the year was roughly $938,000. Managed care organizations and commercial insurers were the responsible payers for most cases (60%). Self-pay was noted for 24%. CONCLU-SIONS: Acute alcohol intoxication among those of college age results in a substantial direct medical cost, as well as an opportunity cost for ED resources during the year, particularly at the start of the school year.
PMH3

QUALITY-ADJUSTED LIFE YEARS GAINED WITH BUPRENORPHINE TREATMENT FOR OPIATE ADDICTION
Campbell HM 1 , Raisch DW 1 , Ling W 2 1 VA Cooperative Studies Program, Albuquerque, NM, USA; 2 David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
OBJECTIVES:
To determine quality-adjusted life-year (QALY) gains associated with buprenorphine treatment for opiate addiction, and estimate the potential cost savings of this treatment from the societal perspective. METHODS: In a randomized clinical trial of buprenorphine therapy, subjects completed the short-form-36 (SF-36) at baseline and every four weeks through week-16, creating up to five data collection points for each patient. We converted SF-36 data to SF-6D to calculate QALYs for each patient-month through published techniques based upon standard gamble methods. Dependent t-tests were used to identify significant differences in QALYs at baseline versus QALYs at the end of each month. Our base case used a buprenorphine 12 mg/day dosage plus annual buprenorphine treatment clinic costs ($2356/person). We incorporated social costs of untreated opiate addiction from the literature ($42,957/personyear) and performed a sensitivity analysis using 8 mg and 16 mg buprenorphine dosages. RESULTS: Due to dropouts, our sample size was 100, 80, 69, 59, and 44 patients at baseline and months one-four, respectively. QALY values (mean ± SD) for each month were: 0.734 ± 0.091 at baseline, 0.761 ± 0.068 at month-one, 0.751 ± 0.087 at month-two, 0.754 ± 0.087 at month-three, and 0.757 ± 0.090 at month-four. Thus, an improvement of 0.027 QALYs (P = 0.008) between baseline and month-one occurred (95% CI = 0.007-0.047). There were no other significant improvements, possibly due to patient dropouts. The sensitivity analysis showed direct medical costs for buprenorphine treatment ranged from $4206 to $6056 per person-year. By incorporating societal costs of untreated opiate addiction, a savings of $36,901 to $38,752 per person-year was estimated. CONCLU-SIONS: From a societal perspective, buprenorphine treatment saves money and increases QALYs. For every 37 (95%CI = 21-143) patients treated there is a gain of one QALY. Widespread adoption of proper office-based buprenorphine treatment is clearly indicated; undertreatment leads to exorbitant social costs without QALY gains.
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COST-EFFECTIVENESS OF ALPRAZOLAM IN ANXIETY DISORDERS
García-Contreras F, Castro-Ríos A, Nevarez-Sida A, Constantino-Casas P, Contreras-Hernández I, Mould J, Garduño-Espinosa J Mexican Institute of Social Security, Mexico City, Mexico OBJECTIVE: To estimate cost-effectiveness of Alprazolam versus Clonazepam, Fluoxetine and Imipramine in anxiety disorders in the Mexican Institute of Social Security (IMSS). METHODS: A cost-effectiveness study was carried out with a time horizon of one year, no discount rate was used. Utilization of resources and effectiveness data were taken from an expert panel of psychiatrists working at the IMSS and private sector. Inclusion criteria for experts were: psychiatrists with more than five years of clinical experience, that were certified by the Mexican Council of Psychiatry and that had experience in using the studied drugs in anxiety disorders. Use of resources included hospitalisation, emergency services, visits, laboratory and diagnostic tests, as well as pocket expenses. Unit costs were taken from Administrative and Financial departments of IMSS. Costs were expressed in 2004 USD. Effectiveness measure was days free of symptoms. Sensitivity analysis was univariate and probabilistic. RESULTS: Annual treatment cost of anxiety disorders with Alprazolam was $13,110, with Clonazepam $13,367, with Fluoxetine $13,423 and with Imipramine $14,803. Effectiveness results were 224 days without symptoms for Alprazolam, 232
